Celiac.com 08/18/2025 - Celiac disease is a condition that affects how the body reacts to gluten, a protein found in wheat, barley, and rye. It can interfere with the absorption of essential nutrients, especially in children. One of the nutrients often impacted is vitamin D, which plays a key role in bone development, immune function, and calcium balance. Although vitamin D can be obtained through sunlight, not everyone living in sunny areas has healthy levels. This study looked at children with newly diagnosed celiac disease in Uzbekistan, a country with over 300 days of sunshine per year, to see whether they still suffered from vitamin D deficiency—and how this deficiency affected their health.

Purpose of the Study

The researchers set out to explore two main questions: First, what are the levels of vitamin D in children with newly diagnosed celiac disease who live in a sunny climate? Second, how do vitamin D levels relate to other health markers, such as growth, bone health, and blood chemistry?

Who Was Studied

The study involved 60 children between the ages of 1 and 16 years who had recently been diagnosed with celiac disease. These diagnoses were made using established international guidelines. The average age of the children was around 6 years old. Their results were compared to those of 31 healthy children of similar age who did not have celiac disease. Blood tests were taken from all participants to measure levels of vitamin D, calcium, phosphorus, a bone enzyme called alkaline phosphatase, and a hormone called parathormone that regulates calcium in the body.

Key Findings

Low Vitamin D Levels Despite High Sun Exposure

One of the most surprising results was that even in a country with intense year-round sunlight, children with celiac disease had significantly lower levels of vitamin D than healthy children. On average, their vitamin D levels were less than one-third of the levels found in the control group.

Specifically, 80 percent of children with celiac disease had a clear vitamin D deficiency, meaning their blood levels were below 20 nanograms per milliliter. A concerning 25 percent of them had very severe deficiency, with levels under 10 nanograms per milliliter. The remaining 20 percent had vitamin D levels that were considered low but not yet deficient.

Growth and Bone Development Were Affected

Children with lower vitamin D levels often showed signs of stunted growth and poor weight gain. Over 40 percent of the children had noticeable short stature or growth delays. Additionally, visible bone deformations, such as bowed legs or a curved spine, were more common among those with the most severe vitamin D deficiencies. The lower the vitamin D levels, the more likely the child was to show signs of bone or skeletal problems.

Biological Markers of Bone Stress Were Elevated

Children with lower vitamin D levels also showed higher levels of alkaline phosphatase and parathormone. These substances in the blood usually increase when the bones are under stress or when the body is trying to compensate for low calcium levels. The study found an inverse relationship—meaning that as vitamin D went down, these stress markers went up. This suggests that the children's bones were being negatively affected by both the disease and the lack of vitamin D.

Why This Happens Even in Sunny Climates

The results suggest that just living in a sunny area is not enough to guarantee healthy vitamin D levels—especially for children with celiac disease. There are several reasons for this. First, intestinal damage caused by celiac disease can prevent the body from properly absorbing vitamin D from food. Second, children may not be spending enough time outdoors or may wear clothing that covers most of their skin. Third, even when skin is exposed, if the digestive system is inflamed or damaged, it may still struggle to process the vitamin D effectively.

Implications for Children with Celiac Disease

This study sends a clear message: children with celiac disease are at high risk for vitamin D deficiency, even in sunny environments. Low vitamin D levels can lead to serious problems, especially during the years when children are growing rapidly. Stunted growth, poor weight gain, and deformities in bone structure were all associated with low vitamin D in this group.

Because the children in this study were newly diagnosed, their symptoms reflect the kinds of issues that may appear before treatment begins. This means that early diagnosis and attention to vitamin D status can play a major role in preventing long-term health complications. Blood tests that check for vitamin D, calcium, and related markers should be a standard part of managing celiac disease in children.

Conclusion

The findings of this study highlight the importance of monitoring vitamin D levels in children with celiac disease, even in regions with plenty of sunshine. It challenges the assumption that natural sunlight is always enough to prevent deficiency. For parents, doctors, and caregivers, this study reinforces the need for early screening and nutritional support. Supplementing with vitamin D and calcium, correcting intestinal inflammation through a gluten-free diet, and tracking growth closely could all help children with celiac disease achieve better long-term health outcomes.

Read more at: frontiersin.org

Watch the video version of this article:

Celiac.com 08/11/2025 - Celiac disease is an immune disorder triggered by the ingestion of gluten, a protein found in wheat, barley, and rye. While well-researched in many Western countries, data on celiac disease in African nations, including Cameroon, remain limited. To address this gap, researchers conducted a questionnaire-based study to evaluate the potential risk of celiac disease among adults in two Cameroonian regions—urban Wouri and semi-rural Moungo. Their goal was not to diagnose celiac disease directly, but to estimate the risk based on self-reported symptoms and dietary habits.

Method: Using Questionnaires to Assess Risk

The researchers distributed structured questionnaires to adults over the age of 18 at district hospitals in both regions. These questionnaires collected information on symptoms commonly associated with celiac disease, such as gastrointestinal discomfort and fatigue, as well as dietary habits involving gluten consumption. The responses were scored to categorize participants into low, moderate, or high-risk groups. Statistical analysis was then used to explore relationships between risk levels and demographic or lifestyle factors.

Urban vs. Semi-Rural: A Tale of Two Populations

The study found notable differences in risk levels between the two regions. Among urban respondents, 63.4% fell into the high-risk category, while only 0.7% of semi-rural participants did. In contrast, 75.3% of semi-rural respondents were classified as moderate risk, compared to 36.6% of their urban counterparts. These differences align with broader lifestyle and dietary patterns observed in the two areas.

Urban participants tended to be more educated, single, and physically active. They were also more likely to consume gluten-containing foods frequently. Meanwhile, semi-rural participants were more sedentary, consumed fewer wheat products, and had more limited access to processed foods.

Symptom Patterns: A Warning Sign

The study revealed that participants from urban areas reported more frequent and severe symptoms associated with celiac disease. For example, symptoms such as vomiting, diarrhea, constipation, abdominal pain, bloating, and heartburn were significantly more common among urban residents. These individuals also reported more extraintestinal symptoms such as fatigue, headaches, dermatitis herpetiformis, arthritis, and autoimmune diseases.

Interestingly, symptoms like enamel hypoplasia—a dental condition linked to malabsorption—were also more prevalent among high-risk participants, suggesting a deeper, systemic issue beyond temporary gastrointestinal discomfort.

Risk Indicators: More Than Just Gluten

Several factors were associated with moving from a moderate to high-risk category. These included frequent gastrointestinal symptoms, the presence of musculoskeletal issues like arthritis and osteopenia, and autoimmune disorders. Beer consumption also emerged as a significant risk factor, possibly due to its gluten content.

Urban dietary habits, especially the frequent consumption of gluten-containing processed foods, likely play a key role in the elevated risk levels. The questionnaire results indicated that 93.1% of urban respondents consumed gluten regularly, compared to only 10.0% of those in semi-rural areas.

Why the Discrepancy? Possible Explanations

The differences observed between urban and semi-rural populations may not solely reflect true disparities in disease prevalence. Access to healthcare, educational awareness, and willingness to report symptoms are typically higher in urban areas, potentially inflating perceived risk. Additionally, other regional health conditions such as tropical sprue, protozoal infections, and HIV-related enteropathies could mimic celiac-like symptoms, complicating diagnosis.

Still, the study makes a compelling case that celiac disease risk is non-negligible and that urban dietary and lifestyle factors could contribute to higher prevalence.

Study Limitations

This study has limitations. The use of self-reported data introduces the potential for recall bias or symptom misinterpretation. Also, because participants were recruited from hospitals, the sample may be skewed toward individuals with existing health concerns. The absence of diagnostic confirmation via blood tests or biopsies limits the ability to draw firm conclusions about actual prevalence.

Conclusions and Implications for Public Health

The findings suggest that a significant number of Cameroonians, particularly those in urban areas, may be at elevated risk for celiac disease. While this study does not confirm diagnoses, it highlights symptoms and lifestyle factors that align with known celiac disease patterns.

For individuals with celiac disease or gluten sensitivity, this study underscores the importance of recognizing non-digestive symptoms like fatigue, joint pain, and skin conditions. Healthcare professionals in Cameroon and similar regions should be encouraged to consider gluten intolerance in their differential diagnoses.

Looking ahead, more robust studies using serological tests and biopsies are needed to validate these findings. Until then, this questionnaire-based study serves as a critical first step in raising awareness about a potentially underdiagnosed condition in a rapidly changing dietary landscape.

Why This Matters for People with Celiac Disease

For people already diagnosed or suspecting they may have celiac disease, especially in regions like Africa where medical infrastructure is evolving, this study offers validation. It shows that gluten sensitivity is not limited to Western countries and can be influenced by urbanization, diet, and lifestyle. It also calls for better diagnostic protocols, more education for healthcare workers, and increased public awareness. In short, this study begins to build a much-needed foundation for recognizing and managing celiac disease in places where it has historically been overlooked.

Read more at: bmcgastroenterol.biomedcentral.com

Celiac.com 07/31/2025 - For individuals living with celiac disease or gluten sensitivity, eating foods made from wheat, barley, or rye can trigger serious health issues. Pasta, traditionally made from semolina wheat, is a major challenge for those who must avoid gluten. In response to growing demand for gluten-free alternatives, researchers developed and tested a pasta made from brown rice, quinoa, and chickpea flours. This study examined how these ingredients affect the pasta’s nutrition, texture, taste, and cooking quality—and how they compare to traditional wheat pasta.

Nutritional Profile of Gluten-Free Flours

To begin, researchers analyzed the core ingredients: brown rice flour, quinoa flour, and chickpea flour. Each flour offered distinct nutritional benefits. Chickpea flour stood out for its high protein and fat content, while quinoa flour had the most fat overall. Brown rice flour had less fat but was higher in zinc. Chickpea flour also contained significantly more calcium, iron, and potassium compared to the other flours. These nutrients are especially beneficial to individuals with celiac disease, who are often at risk of mineral deficiencies due to poor nutrient absorption.

The study also assessed the essential amino acid content of each flour, which is critical for maintaining muscle and overall health. Chickpea and brown rice flour showed higher amounts of essential amino acids than semolina. Chickpea flour, in particular, had the highest biological value, indicating its proteins are well-utilized by the body. This suggests that chickpea-based pasta could provide a better protein source than conventional pasta.

Texture and Cooking Qualities

The pasta was made in different blends, combining brown rice with varying amounts of quinoa and a consistent amount of chickpea flour. The resulting mixtures were compared to traditional semolina pasta. One major area of testing was pasting behavior, which involves how the pasta ingredients respond to heat and water during cooking. Brown rice and semolina had the highest viscosity—an indication of firmness and structure—while blends with more quinoa had lower viscosity due to quinoa’s unique carbohydrate structure.

When the pastas were cooked, researchers measured changes in weight, volume, and cooking losses. Gluten-free pasta blends, especially those with quinoa and chickpea flour, gained more weight and volume than traditional pasta, indicating strong water absorption and retention. Importantly, cooking losses—how much starch or other materials leach into the cooking water—were lower in the gluten-free blends than in traditional wheat pasta. This is a sign of high-quality pasta, as it suggests less breakdown during cooking.

Color and Appearance

Color plays a big role in how consumers perceive pasta. In this study, as the amount of quinoa flour increased, the pasta became darker and less yellow. The decrease in brightness and yellowness was more noticeable in cooked pasta, likely due to pigment loss in hot water. Despite the color changes, pasta with lower levels of quinoa still had a pleasant appearance. Chickpea and quinoa’s natural pigments affected color, but not to a degree that would make the pasta visually unappealing, especially in modest amounts.

Taste and Consumer Preference

The team also conducted sensory evaluations, asking participants to rate the pasta’s color, flavor, tenderness, stickiness, and overall acceptability. Unsurprisingly, semolina pasta received the highest overall ratings, but some gluten-free blends performed quite well. Pasta with 10% quinoa flour (BRQ1) scored highest among the gluten-free versions. As the percentage of quinoa increased, taste and appearance ratings declined slightly, with BRQ5 (50% quinoa) receiving the lowest flavor score. Still, even the lowest-rated gluten-free pasta scored within an acceptable range, showing that well-formulated blends can meet consumer expectations.

Interestingly, younger participants were more open to trying new food experiences, suggesting that attitudes toward non-traditional pasta may shift over time as gluten-free eating becomes more mainstream.

Texture Testing: Before and After Cooking

Texture is one of the most noticeable differences between traditional and gluten-free pasta. Researchers used a texture analyzer to evaluate the firmness and structural integrity of pasta both before and after cooking. Pasta made from semolina had the highest hardness values, followed by brown rice. As more quinoa was added, uncooked pasta became softer. After cooking, pasta with higher quinoa content also became less firm. While reduced hardness may concern some, many people prefer a tender, slightly chewy texture, and the blends with 10–20% quinoa still met consumer expectations.

The reduced firmness in quinoa-rich pasta is likely due to the unique starch and protein structure in quinoa, which forms a different network compared to gluten proteins. Nonetheless, the texture was still acceptable, especially in the lower-quinoa blends.

Final Recommendations

This study confirmed that gluten-free pasta made with brown rice, chickpea, and up to 20% quinoa flour can closely match the nutrition, texture, and taste of traditional semolina pasta. Among all formulations, the blend labeled BRQ1 (brown rice with 10% quinoa and 10% chickpea flour) was found to offer the best balance of nutrition and consumer appeal.

The inclusion of quinoa and chickpea flours not only boosted protein and fiber content but also improved the pasta’s cooking quality, reduced cooking losses, and introduced essential minerals often lacking in gluten-free diets. These are important considerations for individuals with celiac disease, who are more prone to deficiencies in nutrients like iron, calcium, and zinc.

Why This Matters for People with Celiac Disease

Celiac disease requires lifelong adherence to a gluten-free diet, but avoiding gluten should not mean compromising on nutrition or enjoyment. This study offers promising insights into how alternative grains and legumes—specifically brown rice, quinoa, and chickpeas—can be combined to create high-quality gluten-free pasta that delivers on both taste and health benefits.

People with celiac disease often struggle with poor nutrient absorption and digestive issues, making it crucial to choose foods that are not only gluten-free but also rich in protein, fiber, and essential minerals. The pasta blends developed in this research meet those needs and have the potential to be scaled up for commercial production. If widely adopted, these recipes could provide better dietary options for the gluten-free community and help improve nutritional outcomes for those living with celiac disease.

In conclusion, gluten-free pasta made with brown rice, quinoa, and chickpea flour can be a smart and satisfying choice—not just an alternative—for people who cannot consume gluten.

Read more at: nature.com

Watch the video version of this article:

Celiac.com 07/30/2025 - This study examined how expectations, rather than the actual presence of gluten, may influence symptoms in people with chronic pain conditions such as fibromyalgia, irritable bowel syndrome, and headaches. By using Open-Label Placebos—pills that patients are told are inactive but may still help—the researchers explored whether changing a person’s mindset could reduce pain and digestive issues during a gluten challenge. The findings suggest that the mind’s role in pain perception may be more significant than previously thought, especially in fibromyalgia.

Why Examine Gluten and Placebos in Chronic Pain?

Many individuals with chronic pain conditions turn to special diets, such as gluten-free eating, in hopes of symptom relief. While some people report benefits, scientific proof has been inconsistent. This study aimed to understand whether the symptoms people report from gluten might be influenced more by what they expect than by what they actually consume. The researchers focused particularly on fibromyalgia, a condition where patients often experience widespread pain without a clear cause, and where food-related symptom triggers are often reported.

How the Study Was Designed

The study included 26 participants, mainly with fibromyalgia, though some also had chronic headaches or irritable bowel syndrome. Each person took part in a food challenge involving porridge that either did or did not contain gluten. Importantly, participants did not know which version they were eating.

In addition to this food challenge, everyone received a placebo pill. These were called “open-label placebos” because the participants were told the pills had no active ingredients. However, they were given different types of instructions:

• One group received neutral instructions, simply describing the pill.
• Another group received positive instructions, which emphasized that the pill could help relieve symptoms like pain or discomfort.

The researchers then measured changes in participants’ pain levels and digestion before and after eating the porridge.

Key Findings: The Power of Positive Thinking

1. Positive Instructions Reduced Pain in Fibromyalgia Patients

Among people with fibromyalgia, those who were told the placebo might help experienced less pain after eating—even if they consumed actual gluten. Meanwhile, those who received neutral instructions actually reported more pain. This suggests that simply believing a treatment will help can make a real difference in how someone experiences pain.

2. Expectations Predict Outcomes

The link between expectation and outcome was clear: people who expected to feel better were more likely to report pain relief. Those who expected little to no benefit were less likely to improve. This effect was particularly strong in fibromyalgia patients and was less pronounced in those with irritable bowel syndrome or headaches.

3. Placebos Did Not Help with Digestive Symptoms

Interestingly, while the placebos helped reduce pain in some patients, they had no noticeable effect on digestion. Participants still experienced temporary indigestion after the food challenge, whether they consumed gluten or not, and regardless of the type of instruction they received.

4. Gluten Had No Significant Effect

Whether the porridge contained real gluten or not didn’t make a difference in pain or digestion outcomes. This suggests that the idea of gluten might be more powerful than gluten itself for some individuals. People may be experiencing a “nocebo effect”—a negative reaction caused by the belief that something will harm them, even if it doesn’t.

Exploring the Role of Placebo in Different Conditions

The study included people with three different types of chronic pain:

• Fibromyalgia: These patients seemed most responsive to the expectation-based intervention. Since they experience chronic pain that isn’t caused by physical damage, their symptoms may be particularly sensitive to psychological and emotional factors like expectation and belief.
• Irritable Bowel Syndrome: Patients with irritable bowel syndrome didn’t show significant pain changes. Some may not have had symptoms when the study began, making it harder to detect improvements. IBS and fibromyalgia share features like heightened sensitivity and fatigue, but the placebo effect was weaker in IBS participants.
• Chronic Headache: All patients with headaches experienced a reduction in pain, regardless of the presence of gluten or type of placebo instruction. However, due to the small number of participants in this group, the findings were considered exploratory and not conclusive.

Why This Study Matters for Celiac Disease and Gluten Sensitivity

Although this study did not include participants with celiac disease, its findings may still resonate with people who suspect they have gluten sensitivity but do not test positive for celiac. Many such individuals report gluten-related symptoms despite no medical confirmation of intolerance. This research shows that expectations may play a larger role than previously thought in how gluten affects the body—at least when it comes to pain.

For those with confirmed celiac disease, this study does not suggest that eating gluten is safe. Celiac disease is an autoimmune condition where gluten causes damage to the small intestine, and strict gluten avoidance remains essential. However, for people without celiac disease but who feel worse after eating gluten, it raises the possibility that psychological mechanisms like expectation and belief may be contributing to symptoms.

The Role of Open-Label Placebos

This study adds to the growing body of research showing that placebos can help—even when people know they are taking a placebo. This makes the treatment ethical and transparent, especially when used alongside other care. Open-label placebos could offer a safe, drug-free option for people with chronic pain, helping them gain some relief without side effects.

Interestingly, the study also shows that the way information is delivered—whether instructions are positive or neutral—can significantly change how people feel. This emphasizes the importance of how healthcare providers communicate with patients.

Conclusion: Shifting the Focus from Gluten to the Mind

This study suggests that for some people with chronic pain, particularly fibromyalgia, the belief that gluten causes harm may be more powerful than gluten itself. Pain perception was significantly influenced by expectations, especially when those expectations were shaped positively. While open-label placebos did not reduce digestive symptoms, they did reduce pain in some cases.

These findings do not invalidate real experiences of pain or discomfort after eating gluten. Instead, they open the door to new, more holistic approaches that combine diet, psychological care, and expectation management. For people navigating gluten sensitivity without a celiac diagnosis, this research suggests that the brain’s role in pain and symptom development deserves more attention—and may hold the key to better outcomes.

Read more at: frontiersin.org
 

Watch the video version of this article:

Celiac.com 07/24/2025 - Aluminum has been used as an ingredient in childhood vaccines for nearly a century. Its role as an adjuvant — a substance added to vaccines to enhance the body’s immune response — has made it a standard component in many routine immunizations. However, concerns have continued to circulate about whether aluminum in vaccines might contribute to the development of chronic illnesses such as autoimmune diseases, allergies, and neurodevelopmental disorders in children. Despite widespread vaccine use, large-scale safety data addressing this specific concern have been limited.

To explore this issue thoroughly, researchers in Denmark conducted one of the largest studies of its kind, analyzing health data from over one million children. Their aim was to determine whether exposure to aluminum-containing vaccines during the first two years of life increases the risk of developing any chronic health conditions later in childhood.

Study Design and Population

The study examined 1,224,176 children born in Denmark between 1997 and 2018. All participants were alive and living in Denmark by the age of two. The researchers collected data from Denmark’s national health registries, which track every child’s birth, vaccination history, and health outcomes over time.

The vaccination records included specific details about the number and type of vaccines administered, as well as how much aluminum each vaccine contained. This made it possible to estimate the total aluminum exposure each child received from vaccines during the first two years of life. Most children received vaccines containing between 0.125 mg and 1.00 mg of aluminum. Only 1.2 percent of children received no aluminum-containing vaccines by age two.

Types of Health Conditions Studied

Researchers evaluated the development of 50 different chronic conditions in children. These were grouped into three broad categories:

• Autoimmune diseases: including Type 1 diabetes, juvenile arthritis, and Henoch-Schönlein purpura.
• Atopic or allergic conditions: including asthma, eczema (atopic dermatitis), and allergic rhinitis.
• Neurodevelopmental disorders: including autism spectrum disorder and attention-deficit hyperactivity disorder.

Main Results of the Study

The results were clear: aluminum exposure from vaccines in the first two years of life was not associated with an increased risk of developing any of the 50 chronic conditions studied. In fact, when researchers looked at the risk of these conditions across varying levels of aluminum exposure, they found no meaningful increase in disease rates.

For every 1 milligram increase in aluminum exposure, the adjusted risk estimates were:

• Autoimmune disorders: 0.98 times the baseline risk (slightly lower risk, but not statistically significant).
• Atopic or allergic conditions: 0.99 times the baseline risk (no meaningful change).
• Neurodevelopmental disorders: 0.93 times the baseline risk (slightly lower risk).

When analyzing individual conditions, the researchers found no strong evidence linking aluminum to any specific illness. For example, Type 1 diabetes had a hazard ratio of 1.03, juvenile arthritis was at 1.05, and asthma — the most commonly diagnosed condition — had no increased risk.

Study Strengths and Limitations

The primary strength of the study lies in its large scale and comprehensive national data. It used real-world health records for more than one million children, making the findings highly reliable. The researchers were able to adjust for many potential confounding factors, such as age, sex, family health history, and socioeconomic status.

However, one limitation is that the study did not include a manual review of individual medical records. This means that while registry data is highly accurate, subtle clinical details may not have been captured. In addition, because the study looked at a broad population, it cannot entirely rule out very small increases in risk for rare conditions.

What This Means for Families and Public Health

This study offers strong reassurance to parents and public health officials alike. It supports the conclusion that aluminum-containing vaccines, which are part of standard childhood immunization schedules around the world, do not increase the risk of developing chronic autoimmune, allergic, or neurological diseases. For most conditions examined, even a moderate risk increase was ruled out.

The findings directly challenge claims by vaccine critics who have long argued that aluminum in vaccines is harmful. In particular, public figures have raised concerns that aluminum might trigger allergies or contribute to autism — beliefs that this study finds no evidence to support.

Aluminum continues to be a necessary and effective component in many vaccines, helping ensure a strong immune response in young children. Its safety profile, as confirmed by this large Danish study, further reinforces the importance of continuing routine childhood immunizations.

Why This Study Matters to People with Celiac Disease

People with celiac disease often have autoimmune concerns and may be especially cautious about anything that might trigger immune responses, including vaccinations. This study is important because it shows no link between aluminum in vaccines and autoimmune conditions — including those affecting the digestive system.

While celiac disease itself was not directly studied, the results support the broader safety of childhood vaccinations in populations at risk for autoimmune disease. For parents of children with a family history of celiac disease or other immune-related conditions, this research provides valuable peace of mind: aluminum-containing vaccines are not likely to contribute to autoimmune activation or related complications.

As misinformation about vaccine ingredients continues to spread, high-quality research like this plays a crucial role in helping families make informed, science-based decisions about their children’s health.

Read more at: acpjournals.org

Celiac.com 07/14/2025 - Celiac disease is an autoimmune disorder where the immune system attacks the small intestine in response to gluten, a protein found in wheat, barley, and rye. While genetics play a major role in celiac disease, only about half of the genetic risk factors are currently understood. This study aimed to uncover new genetic variants linked to celiac disease by analyzing DNA from over 52,000 adults, including both previously diagnosed patients and newly identified cases through screening.

The research team discovered 15 new genetic variants associated with celiac disease, with one of the strongest signals coming from a region on chromosome 5 (5p15.33). This region is also linked to rheumatoid arthritis, suggesting a possible shared genetic pathway between autoimmune diseases.

How the Study Was Conducted

Participant Screening and Diagnosis

The study used data from a large health survey in Norway, where adults were screened for celiac disease using blood tests that detect antibodies against an enzyme called transglutaminase 2 (TG2). Those who tested positive underwent further testing, including small intestine biopsies, to confirm the diagnosis.

This approach helped identify 465 previously undiagnosed cases in addition to 361 known celiac patients, reducing the risk of misclassification that could skew genetic findings.

Genetic Analysis

Researchers analyzed DNA samples using advanced genetic testing methods, examining nearly 25 million genetic variants across the genome. They compared the genetic profiles of celiac patients with those of healthy individuals to pinpoint differences that might contribute to disease risk.

Key Findings

New Genetic Variants Discovered

The study identified 15 previously unknown genetic variants linked to celiac disease. The most notable was in a region called 5p15.33, which contains a long non-coding RNA gene (LINC01019). While the exact function of this gene in celiac disease is unclear, the same region has been associated with rheumatoid arthritis, hinting at a possible shared autoimmune mechanism.

Other newly discovered variants were found near genes involved in:

• Immune cell signaling
• Intestinal barrier function
• Brain and nervous system activity

Interestingly, some of these genes are active not just in the gut but also in the brain, which might explain why some celiac patients experience neurological symptoms like brain fog or fatigue.

Confirmation of Known Genetic Risks

The study also confirmed 41 previously known genetic risk factors for celiac disease, though some appeared less significant in this population. This could be due to differences in genetic backgrounds or the study’s focus on including undiagnosed cases.

Why These Findings Matter for Celiac Disease

Better Understanding of Disease Development

Since only about 3% of people with the main genetic risk markers (HLA-DQ2/DQ8) actually develop celiac disease, these newly discovered variants may help explain why some individuals are more susceptible than others.

Potential for Improved Diagnosis and Treatment

Identifying new genetic links could lead to:

• More accurate screening tests to predict celiac risk.
• New drug targets that could modify immune responses in celiac disease.
• Insights into shared autoimmune pathways, possibly benefiting research on related conditions like rheumatoid arthritis or type 1 diabetes.

Explaining Non-Gut Symptoms

The discovery of genetic variants active in the brain and nervous system supports the idea that celiac disease can affect more than just digestion. This could lead to better recognition and management of neurological symptoms in patients.

Limitations and Future Research

While this study provides valuable insights, it has some limitations:

• The participants were mostly of European ancestry, so findings may not apply to all populations.
• The research did not include children, who often develop celiac disease earlier in life.
• Some genetic signals need further validation to confirm their role in celiac disease.

Future studies should explore:

• How these genetic variants influence immune function.
• Whether they can be used to predict disease progression.
• Possible connections to other autoimmune disorders.

Conclusion: What This Means for People with Celiac Disease

This study significantly advances our understanding of the genetic basis of celiac disease, uncovering new risk factors that could explain why some people develop the condition while others do not. By including undiagnosed cases, the research provides a more complete picture of celiac genetics than previous studies.

For those living with celiac disease, these findings offer hope for:

• Better diagnostic tools to catch the disease earlier.
• Personalized treatments based on genetic risk.
• Deeper insights into how celiac disease affects the whole body, not just the gut.

While more research is needed, this study brings us closer to unraveling the full genetic story behind celiac disease—and potentially improving lives for millions affected by it.

Read more at: nature.com

Celiac.com 07/04/2025 - This study explored how a process called deamidation affects gliadin, a major component of gluten found in wheat. Gliadin is known to cause serious health issues for people with celiac disease or wheat allergies. The researchers wanted to find out if deamidation could make gliadin less harmful by changing how it behaves in the body after digestion.

More specifically, the study focused on how deamidated gliadin peptides (smaller protein pieces created during digestion) behave in terms of:

• How they cluster together (self-assembly)
• How they move through the protective mucus in the gut
• Whether they damage the cells that line the intestines

The hope is that understanding these changes could lead to safer food products for people sensitive to gluten.

Why Gliadin Causes Problems in the Gut

Gliadin makes up 40–50 percent of wheat gluten and contributes to the stretchiness of dough. But for people with celiac disease or other wheat-related disorders, gliadin is a major trigger for inflammation and damage.

Here’s how it works:

1. After someone eats gluten, their digestive system breaks gliadin down into smaller pieces called peptides.
2. Some of these peptides are very sticky and able to form tiny particles that resemble surfactants, meaning they can interact with cell membranes.
3. These particles easily pass through the mucus barrier that normally protects intestinal cells.
4. Once they reach the surface of intestinal cells, the particles interact with cell membranes and may even damage or destroy them.

This damage allows the peptides to go deeper into the intestinal lining, where they can activate the immune system. This sets off the chronic inflammation seen in celiac disease.

What Is Deamidation and Why Might It Help?

Deamidation is a chemical process that changes specific parts of a protein. It converts certain neutral amino acids—like glutamine and asparagine—into acidic ones, such as glutamic acid or aspartic acid. This change introduces more negative electrical charges to the protein structure.

Researchers believe this process could:

• Make gliadin peptides less likely to form harmful clusters
• Reduce their ability to pass through mucus
• Limit their capacity to damage intestinal cells

Since gliadin contains a lot of glutamine, it’s especially susceptible to deamidation, which makes it a good candidate for modification.

In this study, researchers used citric acid—a safe and commonly available food acid—to gently deamidate gliadin and then investigated the effects.

How Deamidation Changed Gliadin Peptides

The research team treated gliadin with different levels of deamidation using citric acid. They then digested the proteins in the lab using enzymes similar to those found in the human stomach and intestines.

Here’s what they discovered:

1. Shorter, More Polar Peptides Were Formed

When gliadin was only slightly deamidated (less than 20 percent), the peptides that resulted after digestion were shorter and more polar, meaning they were more attracted to water. This made the peptide clusters smaller and more spherical in shape—less threatening to intestinal health.

2. Moderate Deamidation Changed the Shape and Size of Particles

At a moderate level of deamidation (around 26 percent), the peptides became more negatively charged. This changed the way they clumped together. Instead of forming round particles, they formed long, string-like shapes. These changes were driven by increased electrical interactions between the peptide molecules.

Improved Mucus Permeation, but Reduced Cell Damage

The study also looked at how easily these modified peptides could pass through a simulated mucus barrier, and whether they would harm intestinal cells (specifically Caco-2 cells, a model for human intestinal lining).

Key Findings:

• Mucus Penetration: Deamidated peptides moved through the mucus more efficiently due to their smaller or more flexible structures.
• Less Harm to Cells: Although the peptides could still pass through the mucus, they did not harm the intestinal cells the same way untreated gliadin peptides did. This was likely because the increased negative charge made them less likely to stick to and disrupt the cell membranes.

In untreated gliadin, positively charged regions (such as lysine and arginine) on the surface of the peptide clusters interact strongly with negatively charged components of cell membranes, causing damage. Deamidation weakens this attraction, reducing the peptides’ destructive potential.

How the Structural Changes Were Measured

To support their conclusions, the researchers used a variety of scientific tools to look at the gliadin peptides:

• SDS-PAGE to measure protein size
• FT-IR and fluorescence spectroscopy to examine protein folding
• Transmission electron microscopy to visualize particle shape
• HPLC-MS/MS to identify peptide sequences
• Cell culture studies to measure how peptides affected living intestinal cells

These techniques confirmed that deamidation not only changed the structure of the gliadin proteins but also their behavior in the digestive system.

Why This Matters for People with Celiac Disease

This study is important because it suggests a way to reduce the harm caused by gluten proteins without removing them completely. While avoiding gluten is the only treatment for celiac disease right now, this research points toward safer food processing methods that could one day lessen the risk of accidental gluten exposure.

By modifying gliadin through deamidation:

• The resulting peptides may be less likely to damage the gut lining.
• This could mean fewer immune triggers for people with gluten sensitivity or celiac disease.
• Food products made from deamidated gluten might be more tolerable in the future, though much more research is needed before this becomes a real-world option.

Conclusion: A Step Toward Safer Gluten for Sensitive Individuals

The researchers successfully demonstrated that deamidation changes the way gliadin peptides behave after digestion. These changes—especially shorter peptide length, altered particle shape, and reduced interaction with intestinal cells—help make the peptides less harmful. The findings support the potential for deamidation to be used as a food processing method to reduce gluten-related damage.

While this study was conducted in a lab and more clinical testing is needed, it opens a promising door for creating safer wheat-based products for people with celiac disease or gluten sensitivity.

Read more: sciencedirect.com

Celiac.com 07/02/2025 - People with celiac disease or wheat allergy must avoid even tiny amounts of gluten, a group of proteins found in wheat, barley, and rye. Eating gluten triggers a strong immune reaction in people with celiac disease, damaging their intestines and leading to a range of symptoms from digestive problems to long-term nutrient deficiencies. To help protect these individuals, food labeled as “gluten-free” must contain less than 20 milligrams of gluten per kilogram of food.

Testing for gluten in food products is therefore essential. The most common method used today is a laboratory test called an enzyme-linked immunosorbent assay, which uses antibodies to detect specific parts of gluten proteins. However, these tests can sometimes give inconsistent or inaccurate results. They often focus on just one part of gluten—called gliadin—and may not account for other gluten components like glutenin. This inconsistency becomes a problem when trying to ensure safety across different types of food or when new gluten-free products enter the market.

A newer method known as mass spectrometry has the potential to improve the accuracy of gluten testing. This method works by detecting small fragments of proteins, called peptides, and can be much more specific than current techniques. However, to use it effectively, scientists need to find a way to convert the amount of peptide measured into the total amount of gluten protein present. That’s where this study comes in.

Developing a Better Gluten Detection Method

The researchers set out to solve a key challenge: how to turn the amount of gluten peptides measured by mass spectrometry into a reliable estimate of the total gluten protein in a food sample. To do this, they started by creating a set of well-defined protein samples from wheat flour using a classical process called Osborne fractionation. This process separates the different types of proteins in wheat, including gliadins and glutenins.

Once the protein fractions were isolated, they were analyzed using various laboratory methods to confirm their composition. This included examining how the proteins reacted with antibodies and testing them with blood samples from people who have IgE-mediated wheat allergies (a different type of immune reaction than celiac disease). These tests ensured that the protein fractions were clinically relevant and contained the types of gluten that cause real-world reactions in sensitive individuals.

Next, the team identified four promising peptide markers—small protein fragments that could be reliably detected using mass spectrometry. These markers were carefully selected from key parts of gluten proteins known to cause immune reactions in both celiac disease and wheat allergy. Two of the markers came from a type of gliadin protein, one came from a gamma-gliadin protein, and one from a low-molecular-weight glutenin protein. Some of these markers also overlapped with regions known to be toxic to people with celiac disease.

The selected peptides were then synthesized with a heavy isotope label, a special chemical tag that makes them easier to detect and measure accurately in mass spectrometry.

Establishing Conversion Factors: From Peptide to Protein

The next challenge was determining how to translate the amount of peptide detected into the amount of total gluten protein in a food sample. The researchers explored two approaches: one based on theoretical calculations and another based on experimental data. They compared how well each approach worked for converting peptide measurements into actual gluten protein amounts.

Experimental methods turned out to be more accurate. In particular, when they used protein fractions enriched for glutenin, they got results that closely matched those obtained using a completely different test known as the Dumas method (which measures total nitrogen in a sample to estimate protein content).

One of the peptides, named VQQIPVVQPSIL, showed excellent sensitivity, meaning it could detect very low levels of gluten in a sample—around 10 milligrams of gluten per kilogram of food. This is below the international threshold of 20 milligrams per kilogram for gluten-free labeling, making it suitable for real-world applications.

Real-World Relevance and Clinical Validation

To make sure the test would work in practical settings, the researchers applied it to real wheat flour samples. The results confirmed that the method could detect and quantify gluten effectively. They also validated the clinical relevance of the protein markers by showing that the gluten fractions reacted with blood from patients with wheat allergies.

Importantly, some markers used in this test include known toxic fragments that are responsible for triggering celiac disease. This makes the method particularly valuable, because it targets the components of gluten that matter most for people with gluten sensitivity or immune responses. It also offers a more complete picture by including peptides from both gliadin and glutenin proteins—unlike older tests that only focus on gliadin.

Why This Study Matters to People with Celiac Disease

This study is an important step forward in gluten detection. For people with celiac disease, even trace amounts of gluten can cause serious health problems. That means food manufacturers and regulators need the most accurate testing methods available to ensure safety and prevent accidental exposure.

The mass spectrometry-based method described in this research offers a promising alternative to current antibody-based tests. It provides more precise and consistent results and can detect parts of gluten that are known to trigger celiac disease. It also includes a clear way to convert the amount of peptide detected into an estimate of total gluten protein, making it suitable for regulatory use.

If this method is adopted more widely, it could improve the accuracy of gluten-free labeling and increase consumer confidence in the safety of gluten-free products. For those living with celiac disease, better testing means fewer health risks, less stress, and more freedom in choosing what to eat.

Final Thoughts

In summary, this study developed a new, highly sensitive method for measuring gluten in food using mass spectrometry. By selecting key peptide markers and creating accurate conversion factors, the researchers laid the groundwork for a more reliable gluten detection system. Their work could help food producers meet labeling requirements more accurately and help protect people with celiac disease from unintended gluten exposure. As gluten-free diets become more common and food options expand, this kind of scientific advancement becomes even more essential.

Read more at: pubs.acs.org

Celiac.com 06/30/2025 - Celiac disease is often associated with digestive problems like chronic diarrhea, but it can also impact a child's growth and development in ways that aren’t immediately obvious. This study explored how common celiac disease is in children with long-term diarrhea and what factors might help predict who has the condition. Conducted at a hospital in Peshawar, Pakistan, the study sheds light on why doctors should keep celiac disease in mind when evaluating children with digestive issues.

Understanding the Purpose of the Study

The main goal of this research was to find out how frequently celiac disease occurs in children who suffer from chronic diarrhea. Chronic diarrhea—when loose stools continue for several weeks—can have many causes, but celiac disease is one possibility that doctors sometimes overlook. Since untreated celiac disease can lead to serious complications like poor growth, nutrient deficiencies, and even some types of cancer, identifying it early is critical.

How the Study Was Conducted

The study included 165 children under 14 years of age who were admitted to the hospital with a history of chronic diarrhea. To be included, the children had to have diarrhea lasting for a significant period, but they were excluded if they were already on a gluten-free diet without a formal diagnosis, had bloody diarrhea, or had previously undergone abdominal surgery.

Each child underwent a blood test to detect antibodies associated with celiac disease. Researchers also collected information about each child's age, gender, weight, height, and family history of celiac disease. The children were then grouped based on whether they had normal height and weight for their age and whether they had any relatives with celiac disease.

The analysis compared children who tested positive for celiac disease to those who did not, looking for trends that could point to a higher risk of having the condition.

Key Findings: How Common Is Celiac Disease?

Out of the 165 children in the study, 22 were diagnosed with celiac disease. This means roughly 13 percent of the children with chronic diarrhea had celiac disease—a much higher rate than in the general population. This high percentage shows how important it is to consider celiac disease as a possible diagnosis in children with ongoing diarrhea.

Interestingly, the study found that some expected risk factors, like age, gender, or being underweight, did not strongly predict whether a child had celiac disease. However, two factors—short stature and family history—were more closely associated with the condition.

Short Stature as a Red Flag

One of the most significant findings was the strong link between celiac disease and short stature. Children who were shorter than average for their age were much more likely to have celiac disease than those who were of average height. In fact, nearly 29 percent of children with short stature had celiac disease, compared to just 6 percent of children with normal height.

This suggests that poor growth could be an important sign of undiagnosed celiac disease in children who also have chronic diarrhea. Since malnutrition caused by the condition can impair growth, it makes sense that height might be more telling than weight. The results support the idea that children with unexplained short stature should be evaluated for celiac disease, especially if they also have digestive symptoms.

Family History and Genetic Risk

Another factor that initially appeared to predict celiac disease was family history. Children who had a parent or sibling with celiac disease were more likely to be diagnosed themselves. However, when researchers adjusted for other factors, family history was no longer a strong predictor on its own.

This doesn’t mean family history isn’t important—it still reflects a genetic risk—but it suggests that other signs, like poor growth or digestive symptoms, may be even more useful for spotting potential cases.

Why Weight May Be Less Helpful Than Expected

Being underweight has long been considered a classic sign of celiac disease. But in this study, children with low weight were not significantly more likely to have the condition than those with normal weight. This supports a growing body of research showing that children with celiac disease can appear healthy or even overweight.

For parents and doctors, this finding is important. It means that a child’s weight alone should not rule out or confirm celiac disease. Even children who look well-nourished may be dealing with silent damage to their intestines caused by gluten.

Comparison with Other Countries

The study’s results align with similar research conducted in other parts of the world. In countries like India and Bangladesh, the percentage of children with chronic diarrhea who also have celiac disease ranges from about 12 to 35 percent, depending on how the studies were conducted. This wide range shows that geographic differences, healthcare access, and how chronic diarrhea is defined all affect the reported rates.

Interestingly, children in developed countries like Canada are often diagnosed at a younger age. This is likely due to better awareness among healthcare providers and easier access to diagnostic tests. In contrast, children in less-resourced settings may go undiagnosed for longer, which can lead to more severe symptoms.

Strengths and Limitations of the Study

One strength of this study is its focus on children in a region where celiac disease is likely underdiagnosed. By using a structured approach and including blood tests for diagnosis, the researchers provided valuable insight into how often celiac disease occurs in this specific group.

However, the study also had some limitations. It was conducted at a single hospital and did not use intestinal biopsies—the gold standard for diagnosis. This means some cases might have been missed, or some children might have been misclassified. Also, the relatively small number of children in the study may limit how broadly the findings can be applied.

Why This Study Matters for Children with Celiac Disease

This study highlights an important message: celiac disease should be considered more often in children with chronic diarrhea, especially when accompanied by poor growth. It also shows that relying on weight or family history alone may not be enough to identify children at risk. Instead, a careful evaluation of symptoms and screening tests can help catch celiac disease early and prevent long-term health problems.

For families and healthcare providers, this research reinforces the importance of staying alert to the less obvious signs of celiac disease. When diagnosed early and managed with a strict gluten-free diet, children with celiac disease can recover well, grow normally, and lead healthy lives.

In Summary:

• About 13 out of every 100 children with chronic diarrhea in this study had celiac disease.
• Short stature was a strong indicator of undiagnosed celiac disease.
• Family history and being underweight were less reliable predictors.
• Early screening and diagnosis are crucial to avoid complications.
• Doctors should not rule out celiac disease just because a child seems well-nourished or lacks a family history.

For families of children with digestive issues, this study is a reminder that persistent symptoms deserve thorough evaluation—and that celiac disease may be hiding in plain sight.

Read more at:  cureus.com

Watch the video version of this article:

Celiac.com 06/20/2025 - Celiac disease is an autoimmune condition triggered by eating gluten, a protein found in wheat, barley, and rye. For people with this condition, the only effective treatment is a strict, lifelong gluten-free diet. While this diet can help control symptoms and prevent long-term damage to the small intestine, it also introduces significant lifestyle challenges. One of the most important, yet often overlooked, areas affected is a person’s relationship with food and how it impacts their everyday life. This new study explores exactly that—how food affects quality of life for people living with celiac disease.

What Is Food-Related Quality of Life?

Food-related quality of life is a term that refers to how food and eating influence a person’s social, emotional, and psychological well-being. It includes everything from enjoying meals with friends and family, to feeling confident when eating out, to the stress and anxiety of avoiding foods that could cause serious illness. For someone with celiac disease, these issues become especially complex. Every bite they take must be carefully monitored to avoid gluten exposure, which can not only trigger symptoms but also lead to long-term health damage.

This study set out to measure food-related quality of life in adults with celiac disease using a specialized questionnaire designed just for this purpose. It also explored which factors—such as age or the number of symptoms—might influence how a person feels about food in their daily life.

Who Participated in the Study?

A total of 138 adults with medically diagnosed celiac disease took part in the study. They answered a questionnaire designed to assess how their condition affects their relationship with food. The group included a mix of ages and slightly more women than men. The average age of participants was just over 52 years old, but people of all adult age groups were included.

In addition to the questionnaire, participants shared basic information about their health and symptoms, including how many ongoing gastrointestinal issues they were dealing with.

What Did the Study Find?

Overall, the research confirmed that food-related quality of life is noticeably affected in people with celiac disease. However, the impact is not the same for everyone. Some groups reported a much more difficult experience than others.

Younger Adults Reported the Most Challenges

The study found that younger adults—especially those between the ages of 18 and 35—had the lowest food-related quality of life scores. These individuals may be at a stage in life where social events often revolve around food and dining out, which can be especially challenging when living with dietary restrictions. Their average score was significantly lower than older adults, who seemed to manage the dietary limitations more easily or had adapted better over time.

More Symptoms = Lower Quality of Life

People who reported having more gastrointestinal symptoms also scored lower on the food-related quality of life scale. Those with four or more ongoing symptoms had a particularly difficult time, suggesting that continued symptoms despite following a gluten-free diet can make eating even more stressful. This might be due to worries about hidden gluten, anxiety over possible contamination, or ongoing damage from past gluten exposure.

Social and Emotional Impact

While the study focused mainly on data and scores, it reflects deeper emotional and social realities. People with celiac disease often face food-based isolation. They may avoid restaurants, travel, or even family gatherings out of fear of getting sick. Some report feeling like a burden or different from others, and many struggle with the constant vigilance required to stay safe. These experiences can take a toll on mental health, self-esteem, and overall enjoyment of life.

What Can Be Done to Improve the Situation?

This study highlights the need for more support for people living with celiac disease—support that goes beyond diet advice. While dietitians can help patients identify safe foods, many people may also benefit from psychological support to cope with the social and emotional effects of their condition. Counseling, support groups, and public awareness efforts could all play a role in helping people live more fully and comfortably with celiac disease.

In particular, younger adults may need targeted support as they navigate school, dating, and social events—all areas of life where food is often a central part. Likewise, individuals who continue to have symptoms despite their best efforts at following a gluten-free diet may need more in-depth medical evaluations and tailored advice to improve their experience with food.

Why This Research Matters for People with Celiac Disease

Celiac disease is often seen as a “diet-managed” condition, but this study shows that the impact of the disease goes far beyond what is on the plate. Food is deeply connected to identity, culture, and community. For people with celiac disease, the constant need for caution can lead to emotional stress, social isolation, and reduced quality of life.

Understanding how food impacts well-being gives healthcare providers and researchers a better starting point for offering real help. This could mean developing better educational tools, creating more inclusive food options, or investing in psychological services for those who need them. By paying closer attention to food-related quality of life, the medical community can improve how celiac disease is treated and understood—not just medically, but also personally.

In short, this research sends a clear message: improving life with celiac disease means more than just removing gluten. It means supporting people in every aspect of how they live, eat, and connect with others.

Read more at: onlinelibrary.wiley.com

Celiac.com 06/19/2025 - For the 1% of the global population with celiac disease and the millions more with gluten sensitivity, wheat has long been a dietary enemy. But a groundbreaking genetic discovery could change that—by deleting key wheat proteins that trigger immune reactions without sacrificing baking quality.

This article explores how scientists are modifying wheat to reduce celiac disease risks, what this means for gluten-sensitive individuals, and whether safer wheat could become a reality in the future.

The Problem: Why Wheat Triggers Celiac Disease

Celiac disease is an autoimmune disorder where gluten—a protein found in wheat, barley, and rye—triggers an immune attack on the small intestine. Even tiny amounts can cause digestive damage, nutrient malabsorption, and long-term health risks.

Key Culprits: Gliadins and Glutenins

• Gliadins (particularly α-gliadins) contain immunodominant epitopes—protein sequences that provoke strong immune reactions in celiac patients.
• Glutenins contribute to dough elasticity but also contain some problematic peptides.
• The D genome of wheat (chromosome 6D) carries the most harmful epitopes, including the highly reactive 33-mer peptide.

For celiac patients, avoiding gluten entirely is currently the only solution. But what if wheat itself could be modified to be less toxic?

The Breakthrough: Deleting Harmful α-Gliadins from Wheat

A 2025 study published in Theoretical and Applied Genetics reveals a major step toward low-immunogenicity wheat. Researchers used gamma radiation-induced mutations to delete α-gliadin genes from wheat’s three genomes (A, B, and D).

Key Findings:

1. Δgli-D2 deletion (on chromosome 6D) had the biggest impact:

• Removed 81% of immunodominant epitopes (including the notorious 33-mer peptide).
• Unexpectedly improved gluten strength—better for breadmaking.
• No negative effects on yield or protein content.

2. Δgli-A2 and Δgli-B2 deletions also reduced harmful peptides but had less effect on baking quality.

3. Combining Δgli-D2 + Δgli-A2 deletions removed even more toxic peptides without harming wheat performance.

Why Does This Matter for Celiac Patients?

• Reduced exposure to major triggers could lower celiac disease risk in genetically susceptible people.
• Not yet "celiac-safe" (other gluten proteins still contain minor epitopes), but a major step forward.
• Future wheat strains could be engineered to be even safer using CRISPR or other gene-editing tools.

Surprising Bonus: Stronger Gluten, Better Baking

Ironically, removing harmful α-gliadins actually improved wheat’s functionality:

How Δgli-D2 Boosts Gluten Strength:

• The D-genome α-gliadins contain 7-cysteine (7-CYS) variants that act as "chain terminators"—limiting gluten polymer growth.
• Deleting them allows glutenin polymers to grow longer, resulting in:
  • Stronger dough
  • Better bread rise
  • Improved elasticity

Real-World Impact:

• Bakers could get higher-quality flour with fewer additives.
• Gluten-sensitive individuals might tolerate small amounts (though more research is needed).

The Future: Toward Truly "Celiac-Safe" Wheat?

While this discovery is promising, fully non-toxic wheat is still years away.

Next Steps in Research:

• Combining deletions (Δgli-D2 + Δgli-A2 + ω-gliadin knockouts) to remove more epitopes.
• Using CRISPR to precisely edit out harmful sequences without losing baking quality.
• Human trials to see if modified wheat reduces celiac reactions.

Challenges Ahead:

• Not all toxic peptides are gone—LMW and HMW glutenins still contain some.
• Regulatory & consumer acceptance—GMO wheat faces skepticism in some markets.
• Strict celiac diets will still be necessary until 100% safe wheat is achieved.

What This Means for Gluten-Sensitive Individuals

Short-Term (Next 5-10 Years):

• New wheat varieties with fewer triggers may enter the market.
• Reduced risk of accidental gluten exposure in processed foods.
• Possible "low-gluten" products for those with mild sensitivities (not celiacs).

Long-Term (10+ Years):

• Potential for "celiac-safe" wheat if all harmful epitopes are removed.
• Reduced celiac disease incidence if children grow up eating safer wheat.

Conclusion: A Hopeful Step Forward

This research proves that science can make wheat safer without sacrificing quality. While fully gluten-free diets remain essential for celiac patients today, the future could bring:

• Wheat with minimal toxicity
• Better-tasting gluten-free alternatives
• Reduced celiac disease risk worldwide

For now, the Δgli-D2 deletion is a major milestone—one that could transform both agriculture and public health.

Key Takeaways:

• Deleting α-gliadins from wheat’s D genome removes 81% of major celiac triggers.
• It also unexpectedly improves gluten strength—better for baking.
• Combined with other deletions, future wheat could be far less immunogenic.
• Not yet safe for celiacs, but a promising step toward "low-gluten" wheat.

Would you try products made from this modified wheat? Let us know in the comments!

Read more at: link.springer.com

Celiac.com 06/12/2025 - For individuals with celiac disease, eating even tiny amounts of gluten can trigger harmful immune reactions that damage the small intestine. While following a strict gluten-free diet is the only treatment, it can be very difficult to avoid accidental exposure. Gluten can hide in processed foods, be present due to cross-contamination in kitchens or food factories, or exist in trace amounts in products labeled “gluten-free.”

Currently, doctors use blood tests and symptom reports to monitor if someone with celiac disease is successfully avoiding gluten. However, these tools are not always reliable, especially for detecting small or occasional gluten exposure. This study looked at a new type of test that detects specific fragments of gluten, called gluten immunogenic peptides, that are excreted in urine and stool. These peptides are resistant to digestion and remain in the body long enough to be measured, making them good indicators of recent gluten intake.

Introducing the Gluten Immunogenic Peptide Tests

Researchers used two tests developed by the company Biomedal: iVYCHECK (a urine test) and iVYLISA (a stool test). These tests can detect whether someone has eaten gluten recently and how much gluten was consumed. The urine test is best for spotting short-term exposure, such as gluten eaten within the last day. The stool test can measure gluten exposure over several days and provides a more detailed picture.

The main goal of the study was to test how well these tools work in real-life conditions. The researchers also wanted to know if people with celiac disease would find these tests helpful in managing their diet.

How the Study Was Conducted

The study included 21 people. Sixteen participants were following a gluten-free diet, and most had a confirmed diagnosis of celiac disease. Five people without any dietary restrictions served as the control group.

Over a 9-day period, all participants were asked to keep a detailed food and symptom diary. They recorded what they ate, whether it was homemade or from a restaurant, and noted any symptoms they experienced. They also provided urine and stool samples on days 5, 7, and 9 of the study.

The tests were used to analyze these samples for gluten peptides, and the results were compared with what people reported in their food diaries.

What the Tests Found

The results showed that the stool test was highly accurate when used to confirm whether someone had consumed gluten. It correctly identified gluten in 97% of the people who ate it and had a strong ability to rule out gluten intake when it wasn’t present (a high “negative predictive value”).

The urine test was even more sensitive—it caught every instance of gluten exposure reported during the study. However, it was not as specific. This means that while it picked up all known exposures, it also occasionally showed positive results even when people claimed not to have eaten gluten, possibly due to hidden gluten in foods or limitations in self-reporting.

One participant who believed they were following a gluten-free diet recorded symptoms in their diary and later discovered high levels of gluten in their stool sample. This incident demonstrated how these tests could uncover accidental gluten exposure that might otherwise go unnoticed.

Interestingly, over half of the people on gluten-free diets showed some level of gluten peptide in their samples. This raises questions about how much gluten is sneaking into “gluten-free” meals or if some positive results could be false positives. More detailed studies would be needed to confirm this.

How Well Did People Accept the Tests?

Most participants were enthusiastic about using these tests. Many saw them as a valuable tool to monitor accidental gluten intake. People were especially interested in using the tests to understand whether small amounts of gluten were slipping into their diet, often without them knowing.

However, not everyone found the tests equally acceptable. Most people preferred the urine test over the stool test, likely due to the convenience of sample collection. The need to keep a food diary for nine days and provide multiple samples may have affected how willing some people were to fully participate.

The researchers noted that parents of children with celiac disease might be especially interested in these tools, as it can be difficult to monitor a child’s food intake at school or social events.

Limitations of the Study

This study relied heavily on self-reported food diaries rather than independent confirmation of what people ate. This makes it harder to say for sure whether some positive test results were due to actual gluten intake or possible test errors.

Additionally, the study did not include blood tests or intestinal biopsies, which are other ways to assess the impact of gluten exposure in people with celiac disease. Including those could have helped determine whether low levels of gluten peptides actually cause harm.

Still, the study offers promising evidence that these tests could be helpful in real-world settings. They may offer more detailed and timely feedback for people trying to avoid gluten and provide doctors with another tool to assess diet adherence.

Why This Matters for People with Celiac Disease

For people with celiac disease, knowing whether gluten is sneaking into their diet is incredibly important. Ongoing gluten exposure, even in small amounts, can cause gut damage, nutritional deficiencies, and other serious health problems.

These new tests may give individuals a clearer picture of their gluten exposure. A negative test result could offer peace of mind, especially when symptoms are unclear or blood tests are inconclusive. Meanwhile, a positive result may alert someone to hidden sources of gluten and encourage stricter avoidance.

As the tests become more available and affordable, they could become an important part of managing celiac disease. They may also help identify accidental exposures before they cause lasting harm. However, further research is needed to determine how often they should be used and how best to interpret low-level detections.

Conclusion

This study shows that measuring gluten peptides in urine and stool is a promising way to detect hidden or accidental gluten exposure in people following a gluten-free diet. These tests are especially useful when symptoms or blood tests are unclear. While more research is needed, these tools may soon become a helpful addition to the standard approach for monitoring celiac disease and helping patients maintain a truly gluten-free lifestyle.

Read more at: onlinelibrary.wiley.com

Watch the video version of this article: